Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -19.02%. However, over the past six months, we’ve seen a stronger performance of -33.41%. The price of LYEL fallen by 44.10% over the last 30 days. And in the last five days, it has surged by 1.81%.
Currently, the stock price of Lyell Immunopharma Inc. (LYEL) is $2.81. In the most recent trading session, the stock underwent a significant upswing, peaking at $2.9075 after opening at $2.88. The stock touched a low of $2.765 before closing at $2.84.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Lyell Immunopharma Inc. had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $8.74 on 09/12/22, while the lowest price during the same period was $1.77 on 04/26/23.
52-week price history of LYEL Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Lyell Immunopharma Inc.’s current trading price is -67.85% away from its 52-week high, while its distance from the 52-week low is 58.76%. The stock’s price range over this timeframe has been between $1.77 and $8.74. The shares of the Healthcare sector company recorded a trading volume of approximately 0.15 million for the day, which was comparatively lower than the average daily volume of 1.04 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Lyell Immunopharma Inc. (LYEL) has experienced a quarterly rise of 28.31% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 647.24M and boasts a workforce of 274 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.60, with a change in price of -0.52. Similarly, Lyell Immunopharma Inc. recorded 991,903 in trading volume during the last 100 days, posting a change of -15.62%.
LYEL’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for LYEL stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
LYEL Stock Stochastic Average
The raw stochastic average for Lyell Immunopharma Inc. over the last 50 days is presently at 84.52%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 81.43%. Further, the company’s Stochastic %K and %D values for the last 20 days were 84.32% and 86.43%, respectively.
